InnoCare Pharma (HKEX: 09969; SSE: 688428), a leading biopharmaceutical company focusing on the treatment of cancer and autoimmune diseases, announced ...
A once-daily, oral tyrosine kinase 2 inhibitor was safe and “highly effective” in adults with moderate to severe plaque ...
TipRanks on MSN4d
InnoCare Pharma Presents Promising Phase II Data for Psoriasis DrugInnoCare Pharma Ltd. ( ($HK:9969) ) just unveiled an update. InnoCare Pharma Ltd. announced the successful presentation of phase II clinical data ...
announced today that the data of the novel TYK2 inhibitor ICP-488 developed by the Company for the treatment of patients with moderate-to-severe plaque psoriasis has been released at the 2025 ...
Efficacy and Safety of a Highly Selective Oral TYK2 Inhibitor, ICP-488, in Patients with Moderate-to-Severe Plaque Psoriasis: A Phase II, Randomized, Double-blinded, Placebo-Controlled Trial The ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback